Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cagrilintide Clear all
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Cagrilintide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Walnut Creek, California • Aurora, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years and older
Enrollment
7,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
119
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

NCT06409130
View directory record Official record
Conditions
Alcohol-related Liver Disease
Interventions
NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

NCT07011667
View directory record Official record
Conditions
Obesity
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
46
States / cities
Costa Mesa, California • San Diego, California • Walnut Creek, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Not yet recruiting Phase 2 Interventional

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

NCT07357740
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CagriSema, Placebo CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Spring Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Cagrilintide, Placebo (matched to Cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Concord, California • Escondido, California • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

NCT06388187
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Costa Mesa, California • Plantation, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
117
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

NCT06323161
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Northridge, California • Miami, Florida • Meridian, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
La Mesa, California • San Diego, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

NCT06323174
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Not yet recruiting Phase 1 Interventional

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

NCT07605052
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide B, Cagrilintide D
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Not yet recruiting Phase 3 Interventional

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrisema, Placebo CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Pelham, Alabama • Hawthorne, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Recruiting Phase 1 Interventional

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

NCT06719011
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

NCT04982575
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide), Placebo (cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Fresno, California • Los Alamitos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
101
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

NCT06716307
View directory record Official record
Conditions
Obesity
Interventions
CagriSema (cagrilintide B and semaglutide I), CagriSema A
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Recruiting Phase 1 Interventional

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

NCT07184086
View directory record Official record
Conditions
Obesity
Interventions
CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 7, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT06534411
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
54
States / cities
Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Not yet recruiting Phase 1 Interventional

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

NCT07607587
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Cagrilintide, Placebo (matched to Cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Walnut Creek, California • Fleming Island, Florida • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
8 Years to 18 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
34
States / cities
Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 7, 2026, 2:53 AM EDT